» Articles » PMID: 20407209

Excessive Cardiac Insulin Signaling Exacerbates Systolic Dysfunction Induced by Pressure Overload in Rodents

Abstract

Although many animal studies indicate insulin has cardioprotective effects, clinical studies suggest a link between insulin resistance (hyperinsulinemia) and heart failure (HF). Here we have demonstrated that excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. Chronic pressure overload induced hepatic insulin resistance and plasma insulin level elevation. In contrast, cardiac insulin signaling was upregulated by chronic pressure overload because of mechanical stretch-induced activation of cardiomyocyte insulin receptors and upregulation of insulin receptor and Irs1 expression. Chronic pressure overload increased the mismatch between cardiomyocyte size and vascularity, thereby inducing myocardial hypoxia and cardiomyocyte death. Inhibition of hyperinsulinemia substantially improved pressure overload-induced cardiac dysfunction, improving myocardial hypoxia and decreasing cardiomyocyte death. Likewise, the cardiomyocyte-specific reduction of insulin receptor expression prevented cardiac ischemia and hypertrophy and attenuated systolic dysfunction due to pressure overload. Conversely, treatment of type 1 diabetic mice with insulin improved hyperglycemia during pressure overload, but increased myocardial ischemia and cardiomyocyte death, thereby inducing HF. Promoting angiogenesis restored the cardiac dysfunction induced by insulin treatment. We therefore suggest that the use of insulin to control hyperglycemia could be harmful in the setting of pressure overload and that modulation of insulin signaling is crucial for the treatment of HF.

Citing Articles

Sacubitril/valsartan improves diastolic left ventricular stiffness with increased titin phosphorylation via cGMP-PKG activation in diabetic mice.

Furukawa N, Matsui H, Sunaga H, Nagata K, Hirayama M, Obinata H Sci Rep. 2024; 14(1):25081.

PMID: 39443532 PMC: 11499646. DOI: 10.1038/s41598-024-75757-8.


Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development.

Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R Rev Cardiovasc Med. 2024; 23(5):165.

PMID: 39077592 PMC: 11273913. DOI: 10.31083/j.rcm2305165.


Quantification of cardiac capillarization in basement-membrane-immunostained myocardial slices using Segment Anything Model.

Zhang Z, Chen X, Richardson W, Gao B, Razi A, Ye T Sci Rep. 2024; 14(1):15344.

PMID: 38961220 PMC: 11222533. DOI: 10.1038/s41598-024-65567-3.


Insulin resistance in the retina: possible implications for certain ocular diseases.

Zheng Z, Yu X Front Endocrinol (Lausanne). 2024; 15:1415521.

PMID: 38952394 PMC: 11215121. DOI: 10.3389/fendo.2024.1415521.


Role of Vasoactive Hormone-Induced Signal Transduction in Cardiac Hypertrophy and Heart Failure.

Dhalla N, Mota K, Elimban V, Shah A, de Vasconcelos C, Bhullar S Cells. 2024; 13(10.

PMID: 38786079 PMC: 11119949. DOI: 10.3390/cells13100856.


References
1.
Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R . Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005; 115(8):2108-18. PMC: 1180541. DOI: 10.1172/JCI24682. View

2.
Debosch B, Treskov I, Lupu T, Weinheimer C, Kovacs A, Courtois M . Akt1 is required for physiological cardiac growth. Circulation. 2006; 113(17):2097-104. DOI: 10.1161/CIRCULATIONAHA.105.595231. View

3.
Matsui T, Li L, Wu J, Cook S, Nagoshi T, Picard M . Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002; 277(25):22896-901. DOI: 10.1074/jbc.M200347200. View

4.
Barger P, Kelly D . Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci. 1999; 318(1):36-42. DOI: 10.1097/00000441-199907000-00006. View

5.
Neubauer S . The failing heart--an engine out of fuel. N Engl J Med. 2007; 356(11):1140-51. DOI: 10.1056/NEJMra063052. View